In a case series of 12 patients with BRAFV600-mutant metastatic melanoma who achieved CR with BRAF/MEK inhibitors and subsequently discontinued treatment, 50% of patients remained relapse-free whereas 50% of patients recurred at a median of 6.6 months after stopping therapy [70]. The gene discussed is BRAF; the disease is metastatic melanoma.